The Medical Letter on Drugs and Therapeutics
Three New Oral Contraceptives
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique, Loestrin 24 Fe and Yaz, have recently been approved by the FDA. All 3 are derivatives of older products.

RATIONALE — Theoretically, shortened hormone-free intervals would reduce hormone withdrawal symptoms, particularly withdrawal bleeding, and decrease the risk of ovulation and pregnancy. One study found that contraceptive regimens with shorter hormone-free intervals suppressed ovarian hormone production more effectively than those with the traditional 7-day interval.1

SEASONIQUE — As with its predecessor Seasonale,2 Seasonique has a 91-day cycle. With both products, active tablets are taken for 84 consecutive days, decreasing the number of withdrawal bleeds annually from 13 with standard 28-day-cycle ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Three New Oral Contraceptives
Article code: 1244a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian